Semax and Selank are both nootropic drugs that are related and have been studied in various contexts:
Development
Both Semax and Selank were developed by the Institute of Molecular Genetics in Russia.
Clinical use
Selank is used to treat generalized anxiety disorder (GAD) and has shown to be effective without the sedating or cognitive side effects of benzodiazepines.
Pharmacology
Selank can modulate gene expression in the GABAergic system, and neurosignaling and neuroreception.
Immunomodulation
Studies have shown that Semax and Selank can correct the cellular and humoral immunogenesis reactions, and phagocytic activity of neutrophils.
Brain connectivity
A study of healthy participants found that Semax and Selank affected functional connectivity between the amygdala and other regions of the brain.
Behavior
Studies have shown that Semax and Selank affect the behavior of rats with parkinsonism.
Research purposes only peptide.
All vials caps in color and size.
